Ampicillin+sulbactam and phosphomycin are now on the list of Vital and Essential Drugs

According to the results of the first meeting in 2018, the Commission of the Ministry of health on the formation of lists of medical preparations decided to include in the list of Vital and Essential Drugs two antibiotics INN ampicillin+sulbactam and phosphomycin.

Ampicillin/sulbactam - one of the most important inhibitor-protected penicillin. The clinical application of this antibiotic is extremely extensive due to the wide range of activity, the possibility of use in the form of monotherapy and activity against a number of pathogens that are resistant to both penicillins and antibiotics of other groups.

Ampicillin / sulbactam as the drug of choice is included in the treatment regimens of most moderate and severe mixed infections, including those in gynecology and surgery. High activity against pneumococci also allows the drug to be used for the treatment of non-hospital pneumonia, empyema of the pleura and lung abscesses. Optimal use of antibiotics is for perioperative antibiotic prophylaxis.

Low toxicity and an optimal safety profile allow the inclusion of ampicillin/sulbactam in the schema of choice for the treatment infections in children from the neonatal period and pregnant women.

Phosphomycin -is an antimicrobial drug that combines the unique properties of an antibiotic, an immunomodulator and a proved ability to neutralize the toxic effects of nephrotoxic antimicrobial and antitumor agents. For a long period of clinical use of Phosphomycin large clinical material has been collected. The material allows to judge the effectiveness of this antibiotic in infectious processes of various localizations and etiology. Today, there is data about the clinical efficacy of the sodium salt of Phosphomycin for the treatment of respiratory tract infections, urinary tract infections, including nosocomial and chronic infections, bacterial meningitis and complications after neurosurgical interventions, bone and joint infections, bacterial endocarditis, bacteria of various etiologies, catheter-associated infections, infections in obstetrics and gynecology.

The really encouraging results of Phosphomycin use are of specific interest and practical significance. Phosphomycin is used for the treatment of infections, caused by polyresistantgram (+) cocci (staphylococci and enterococci) and gram (-) aerobic bacteria (especially Enterobacteria with multiple resistance to other antibiotics); at the same time, resistance to Phosphomycin develops very slowly; reasonable use of Phosphomycin in combination with antimicrobial drugs of other groups allows to achieve clinical and bacteriological effect in case of the failure of previous therapy.

Certainly, the inclusion of these antibiotics in the list of Vital and Essential Drugs is an important and timely measure aimed at overcoming the spread of microbial resistance in hospitals and optimizing the treatment of infections caused by the most problematic bacterial pathogens.

PJSC "Kraspharma" is a Russian producer of hospital antibiotics. In the portfolio of products, in addition to the "traditional" cephalosporins I-IV generations, aminoglycosides and parenteral fluoroquinolones, one of the leading positions is occupied by drugs Ampicillin + sulbactam powder for the preparation of a solution for intravenous and intramuscular administration by doses of 0.5 g+0.25 g, 1.0 g + 0.5 g and 2.0 g + 1.0 g and Phosphomycin powder for the preparation of a solution for intravenous injection by doses of 0.5 g (for pediatric practice), 1 g, 2 g and 4 g. These drugs, due to the appropriate efficacy and safety, are widely used in clinical practice for the treatment and prevention of infections of various localizations.

Back to news list